Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Advanced Solid Tumors

NCT07814248 is registered in ClinicalTrials.gov with TwoStep Therapeutics, Inc. as lead sponsor.

NCT NCT07814248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07814248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Advanced Solid Tumors
Lead sponsor
TwoStep Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 2, 2026
Completion date
December 31, 2028
Enrollment
74 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial, endometrial cancer, esophageal cancer, gastric cancer (gc), head & neck cancer, hnscc, nsclc (non-small cell lung cancer), ovarian cancer